Table 2.
Variables | Comparison for OR | Univariate analysis (n = 111) |
Multivariate analysis (n = 111) |
||||||
---|---|---|---|---|---|---|---|---|---|
OR | 95% CI | p value | OR | 95% CI | p value | ||||
EPIC1 | High versus low expression | 0.727 | 0.298 | 1.774 | 0.484 | 0.278 | 0.082 | 0.935 | 0.039 |
Age | ⩾50 versus <50 years | 1.512 | 0.671 | 3.410 | 0.319 | 0.679 | 0.227 | 2.031 | 0.489 |
T stage | T3–T4 versus T2 | 0.364 | 0.136 | 0.976 | 0.045 | 0.241 | 0.071 | 0.814 | 0.022 |
N stage | N1–N3 versus N0 | 0.795 | 0.210 | 3.007 | 0.736 | 0.495 | 0.085 | 2.896 | 0.435 |
ER status | Positive versus negative | 0.179 | 0.077 | 0.418 | <0.001 | 0.132 | 0.039 | 0.446 | 0.001 |
PR status | Positive versus negative | 0.480 | 0.214 | 1.079 | 0.076 | 1.088 | 0.345 | 3.431 | 0.886 |
HER2 status | Positive versus negative | 3.636 | 1.606 | 8.232 | 0.002 | 6.482 | 2.254 | 18.639 | 0.001 |
Ki67 index | ⩾20% versus <20% | 2.313 | 0.466 | 11.471 | 0.305 | 1.230 | 0.171 | 8.833 | 0.837 |
Bold numerals indicate statistical significance.
CI, confidence interval; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; N stage, nodal stage; OR, odds ratio; PR, progesterone receptor; T stage, tumor stage.